Allogeneic, Off-the-Shelf Virus-Specific T Cell (VST) Therapy Candidates

A deep pipeline of allogeneic, off-the-shelf VST therapy candidates targeting twelve viruses.

A large number of patients suffering from devastating viral diseases currently have limited or no treatment options. To address this, we are advancing a pipeline of allogeneic, off-the-shelf VST therapy candidates to treat or prevent life-threatening viral diseases.

Viralym-M (ALVR105)

Multi-VSTs targeting BK Virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein-Barr (EBV), and Human Herpesvirus-6 (HHV-6)

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Treatment of Virus-Associated Hemorrhagic-Cystitis

Allo-HSCT

Treatment of CMV

Allo-HSCT

Treatment of ADV

Allo-HSCT

Prevention of BKV, CMV, AdV, EBV, HHV-6 and JCV

Allo-HSCT

Treatment of BKV

Kidney Transplant

Treatment of CMV

Solid Organ Transplant

ALVR106

Multi-VSTs targeting Respiratory syncytial virus (RSV), Influenza, Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV)

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Treatment of RSV, Influenza, PIV, & hMPV

Allo-/Auto-HSCT

Treatment of RSV, Influenza, PIV, & hMPV

High-risk general population*

ALVR109

Single-VST targeting SARS-CoV-2

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Treatment of COVID-19

High-risk general population*

ALVR107

Single-VST targeting Hepatitis B (HBV)

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Treatment of HBV

Patients with chronic HBV

ALVR108

Single-VST targeting Human Herpesvirus-8 (HHV-8)

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Treatment of HHV-8

Patients with KS, MCD, or PEL

Definitions

Allo-HSCT: allogeneic HSCT; Auto-HSCT: autologous HSCT; KS: Kaposi Sarcoma; MCD: Multi-centric Castleman Disease; PEL: Primary Effusion Lymphoma; POC: Proof-of-concept; High-risk general population: immunocompromised cancer patients, the elderly, and very young

We Treat High-Risk Individuals

Our allogeneic, off-the-shelf VST therapy candidates benefit patients with T cell deficiencies including transplant recipients, immunocompromised cancer patients, the elderly, and the very young at a higher risk of the devastating consequences of viral disease.

BK Virus
Cytomegalovirus
Adenovirus
Epstein-Bar Virus

Human Herpesvirus-6
Parainfluenza Virus
Human Metapneumovirus
Influenza Virus

Respiratory Syncytial Virus
SARS-CoV-2
Hepatitis B Virus
Human Herpesvirus-8

Bladder

Severe hemorrhagic cystitis
Urinary obstruction
Cystectomy

Brain

Severe encephalitis
Seizure
Memory defect
Progressive Multifocal Leukoencephalopathy

Kidneys

Nephritis
Acute/chronic renal failure
End stage renal disease

Lungs

Pneumonia
Bronchitis
Respiratory failure

Eyes

Retinitis
Blindness

Liver

Chronic hepatitis
Liver cirrhosis
Hepatocellular Carcinoma

Small/Large Intestine

Colitis
Ulceration / perforation
Intestinal bleeding

Malignancy

Kaposi sarcoma
Primary Effusion
Lymphoma (PEL)

Allogeneic, Off-the-Shelf Virus-Specific T Cell (VST) Therapy Candidates

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Target Indication

Target Population

Preclinical

POC Trial (Phase 1b/2)

Pivotal Trial (Phase 3)

Definitions

We Treat High-Risk Individuals

Bladder

Brain

Kidneys

Lungs

Eyes

Liver

Small/Large Intestine

Malignancy

AlloVir is the Global Leader in Developing VST Immunotherapies

Our Pipeline

Our Platform

Our People

Cambridge

Houston

Company